Abstract
Intratumoral hypoxia has long been considered to be a driving force in tumor progression as well as a negative prognostic factor in human cancers. The discovery of hypoxia inducible factors (HIFs), which mediate transcriptional responses to changes in oxygen levels, has renewed enthusiasm for drug discovery and the development of targeted therapies in this field. LW6 represents an important new class of small molecules that inhibit HIF-1; it has been major source for diverse lead compounds including HIF-1α inhibitors. Through a chemical biology approach, LW6-derived chemical probes were successfully utilized for the identification of the direct targeting of a protein in cancer. LW6 provides a valuable platform for the discovery and development of small molecule inhibitors of HIF-1α-dependent tumor progression, metabolic reprogramming, and angiogenesis.
Graphical Abstract
Similar content being viewed by others
References
Ban, H.S., K. Shimizu, H. Minegishi, and H. Nakamura. 2010. Identification of HSP60 as a primary target of o-Carboranylphenoxyacetanilide, an HIF-1α inhibitor. Journal of the American Chemical Society 132: 11870–11871.
Boovanahalli, S.K., X. Jin, Y. Jin, J.H. Kim, N.T. Dat, Y.S. Hong, J.H. Lee, S.H. Jung, K. Lee, and J.J. Lee. 2007. Synthesis of (aryloxyacetylamino)-isonicotinic/nicotinic acid analogues as potent hypoxia-inducible factor (HIF)-1alpha inhibitors. Bioorganic & Medicinal Chemistry Letters 17: 6305–6310.
Borsi, E., G. Perrone, C. Terragna, M. Martello, A.F. Dico, G. Solaini, A. Baracca, G. Sgarbi, G. Pasquinelli, S. Valente, E. Zamagni, P. Tacchetti, G. Martinelli, and M. Cavo. 2014. Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma. Oncotarget 5: 1779–1792.
Bowles, D.W., W.W. Ma, N. Senzer, J.R. Brahmer, A.A. Adjei, M. Davies, A.J. Lazar, A. Vo, S. Peterson, L. Walker, D. Hausman, C.M. Rudin, and A. Jimeno. 2013. A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours. British Journal of Cancer 109: 1085–1092.
Brown, J.M., and W.R. Wilson. 2004. Exploiting tumor hypoxia in cancer treatment. Nature Reviews Cancer 4: 437–447.
Chun, Y.S., E.J. Yeo, E. Choi, C.M. Teng, J.M. Bae, M.S. Kim, and J.W. Park. 2001. Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochemical Pharmacology 61: 947–954.
Chung, J.Y., F.A. Pasha, S.J. Cho, M. Won, J.J. Lee, and K. Lee. 2009. Pharmacophore-based 3D-QSAR of HIF-1 inhibitors. Archives of Pharmacal Research 32: 317–323.
Forsythe, J.A., B.H. Jiang, N.V. Iyer, F. Agani, S.W. Leung, R.D. Koos, and G.L. Semenza. 1996. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Molecular and Cellular Biology 16: 4604–4613.
Ghosh, B., and L.H. Jones. 2014. Target validation using in-cell small molecule clickable imaging probes. MedChemComm 5: 247–254.
Giaccia, A., B.G. Siim, and R.S. Johnson. 2003. HIF-1 as a target for drug development. Nature Reviews Drug Discovery 2: 803–811.
Gleadle, J.M., and P.J. Ratcliffe. 1997. Induction of hypoxia-inducible factor-1, erythropoietin, vascular endothelial growth factor, and glucose transporter-1 by hypoxia: evidence against a regulatory role for Src kinase. Blood 89: 503–509.
Goward, C.R., and D.J. Nicholls. 1994. Malate dehydrogenase: A model for structure, evolution, and catalysis. Protein Science 3: 1883–1888.
Greenberger, L.M., I.D. Horak, D. Filpula, P. Sapra, M. Westergaard, H.F. Frydenlund, C. Albaek, H. Schrøder, and H. Ørum. 2008. A RNA antagonist of hypoxia-inducible factor-1alpha. EZN-2968, inhibits tumor cell growth. Molecular Cancer Therapeutics 7: 3598–3608.
Guo, N., and Z. Peng. 2013. MG132, a proteasome inhibitor, induces apoptosis in tumor cells. Asia‐Pacific Journal of Clinical Oncology 9: 6–11.
Han, S.Y., and S.H. Kim. 2007. Introduction to chemical proteomics for drug discovery and development. Archiv der Pharmazie 340: 169–177. (Weinheim).
Hanahan, D., and J. Folkman. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353–364.
Harris, A.L. 2002. Hypoxia—A key regulatory factor in tumor growth. Nature Reviews Cancer 2: 38–47.
Ihle, N.T., R. Williams, S. Chow, W. Chew, M.I. Berggren, G. Paine-Murrieta, D.J. Minion, R.J. Halter, P. Wipf, R. Abraham, L. Kirkpatrick, and G. Powis. 2004. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Molecular Cancer Therapeutics 3: 763–772.
Jeffery, D.A., and M. Bogyo. 2004. Chemical proteomics and its application to drug discovery. Drug Discovery Today 9: S19–S26.
Kaur, N., Y. Xia, Y. Jin, N.T. Dat, K. Gajulapati, Y. Choi, Y.S. Hong, J.J. Lee, and K. Lee. 2009. The first total synthesis of Moracin O and Moracin P, and establishment of the absolute configuration of Moracin O. Chemical Communications 14: 1879–1881.
Kim, B.S., K. Lee, H.J. Jung, D. Bhattarai, and H.J. Kwon. 2015. HIF-1α suppressing small molecule, LW6, inhibits cancer cell growth by binding to calcineurin b homologous protein 1. Biochemical and Biophysical Research Communications 458: 14–20.
Kotzyba-Hibert, F., I. Kapfer, and M. Goeldner. 1995. Recent trends in photoaffinity labeling. Angewandte Chemie (International Edition in English) 34: 1296–1312.
Lee, K., J.H. Lee, S.K. Boovanahalli, Y. Jin, M. Lee, X. Jin, J.H. Kim, Y.S. Hong, and J.J. Lee. 2007. (Aryloxyacetylamino)benzoic acid analogues: A new class of hypoxia-inducible factor-1 inhibitors. Journal of Medicinal Chemistry 50: 1675–1684.
Lee, K., J.E. Kang, S.K. Park, Y.L. Jin, K.S. Chung, H.M. Kim, K. Lee, M.R. Kang, M.K. Lee, K.B. Song, E.G. Yang, J.J. Lee, and M.S. Won. 2010. LW6, a novel HIF-1 inhibitor, promotes proteasomal degradation of HIF-1alpha via upregulation of VHL in a colon cancer cell line. Biochemical Pharmacology 80: 982–989.
Lee, K., H.S. Ban, R. Naik, Y.S. Hong, S. Son, B.K. Kim, Y. Xia, K.B. Song, H.S. Lee, and M. Won. 2013. Identification of malate dehydrogenase 2 as a target protein of the HIF-1 inhibitor LW6 using chemical probes. Angewandte Chemie (International Edition in English) 52: 10286–10289.
Li, S.H., D.H. Shin, Y.S. Chun, M.K. Lee, M.S. Kim, and J.W. Park. 2008. A novel mode of action of YC-1 in HIF inhibition: Stimulation of FIH-dependent p300 dissociation from HIF-1α. Molecular Cancer Therapeutics 7: 3729–3738.
Naik, R., M. Won, B.K. Kim, Y. Xia, H.K. Choi, G. Jin, Y. Jung, H.M. Kim, and K. Lee. 2012. Synthesis and structure − activity relationship of (E)-phenoxyacrylic amide derivatives as hypoxia-inducible factor (HIF) 1α inhibitors. Journal of Medicinal Chemistry 55: 10564–10571.
Naik, R., M. Won, H.S. Ban, D. Bhattarai, X. Xu, Y. Eo, Y.S. Hong, S. Singh, Y. Choi, H.C. Ahn, and K. Lee. 2014. Synthesis and structure–activity relationship study of chemical probes as hypoxia induced factor-1α/malate dehydrogenase 2 inhibitors. Journal of Medicinal Chemistry 57: 9522–9538.
Park, J.W., Y.G. Chun, K. Bair, and S. Cho. 2007. Compound for treating angiogenesis. US Patent No. 7,226,941 B2. Washington, DC: U.S. Patent and Trademark Office.
Park, J., S. Oh, and S.B. Park. 2012. Discovery and target identification of an antiproliferative agent in live cells using fluorescence difference in two-dimensional gel electrophoresis. Angewandte Chemie (International Edition in English) 51: 5447–5451.
Persidis, A. 1998. Signal transduction as a drug-discovery platform. Nature Biotechnology 16: 1082–1083.
Puppo, M., F. Battaglia, C. Ottaviano, S. Delfino, D. Ribatti, L. Varesio, and M.C. Bosco. 2008. Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1alpha and -2alpha. Molecular Cancer Therapeutics 7: 1974–1984.
Rapisarda, A., B. Uranchimeg, D.A. Scudiero, M. Selby, E.A. Sausville, R.H. Shoemaker, and G. Melillo. 2002. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Research 62: 4316–4324.
Semenza, G.L. 1999. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annual Review of Cell and Developmental Biology 15: 551–578.
Semenza, G.L. 2003. Targeting HIF-1 for cancer therapy. Nature Reviews Cancer 3: 721–732.
Shimizu, K., M. Maruyama, Y. Yasui, H. Minegishi, H.S. Ban, and H. Nakamura. 2010. Boron-containing phenoxyacetanilide derivatives as hypoxia-inducible factor (HIF)-1alpha inhibitors. Bioorganic & Medicinal Chemistry Letters 20: 1453–1456.
Shweiki, D., A. Itin, D. Soffer, and E. Keshet. 1992. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843–845.
Spring, D.R. 2005. Chemical genetics to chemical genomics: small molecules offer big insights. Chemical Society Reviews 34: 472–482.
Varrone, S., E. Consiglio, and I. Covelli. 1970. The nature of inhibition of mitochondrial malate dehydrogenase by thyroxine, iodine cyanide and molecular iodine. European Journal of Biochemistry 13: 305–312.
Welsh, S., R. Williams, L. Kirkpatrick, G. Paine-Murrieta, and G. Powis. 2004. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Molecular Cancer Therapeutics 3: 233–244.
Won, M.S., N.H. Im, S.H. Park, S.K. Boovanahalli, Y.L. Jin, X.J. Jin, K.S. Chung, M. Kang, K. Lee, S.K. Park, H.M. Kim, B.M. Kwon, J.J. Lee, and K. Lee. 2009. A novel benzimidazole analogue inhibits the hypoxia-inducible factor (HIF)-1 pathway. Biochemical and Biophysical Research Communications 385: 16–21.
Xia, Y., M. Won, J.E. Kang, S.K. Park, K. Lee, H.M. Kim, and K. Lee. 2010. Synthesis and biological evaluation of 2-aminoisonicotinic acid analogues as HIF-1α inhibitors. Bulletin of the Korean Chemical Society 31: 3826–3829.
Xia, Y., Y. Jin, N. Kaur, Y. Choi, and K. Lee. 2011. HIF-1α inhibitors: Synthesis and biological evaluation of novel Moracin O and P analogues. European Journal of Medicinal Chemistry 46: 2386–2396.
Xia, Y., H.K. Choi, and K. Lee. 2012. Recent advances in hypoxiainducible factor (HIF)-1 inhibitors. European Journal of Medicinal Chemistry 49: 24–40.
Yeo, E.J., Y.S. Chun, Y.S. Cho, J. Kim, J.C. Lee, M.S. Kim, and J.W. Park. 2003. YC-1: A potential anticancer drug targeting hypoxia-inducible factor 1. Journal of the National Cancer Institute 95: 516–525.
Ziegler, S., V. Pries, C. Hedberg, and H. Waldmann. 2013. Target identification for small bioactive molecules: Finding the needle in the haystack. Angewandte Chemie (International Edition in English) 52: 2744–2792.
Acknowledgments
This study was supported by National Research Foundation (NRF) Grants (2012M3A9C1053532 and 2014R1A2A2A01005455) funded by the Korean Government.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Naik, R., Han, S. & Lee, K. Chemical biology approach for the development of hypoxia inducible factor (HIF) inhibitor LW6 as a potential anticancer agent. Arch. Pharm. Res. 38, 1563–1574 (2015). https://doi.org/10.1007/s12272-015-0632-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-015-0632-5